Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.08.2018 | Case report

Alirocumab

Myalgia and severe depressive disorder: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Madan Raj Poudel MR, et al. Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab/alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis. European Journal of Preventive Cardiology 25 (Suppl. 1): S37 abstr. P210, No. 2, Jun 2018. Available from: URL: http://journals.sagepub.com/doi/full/10.1177/2047487318786175 [abstract] - Germany Madan Raj Poudel MR, et al. Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab/alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis. European Journal of Preventive Cardiology 25 (Suppl. 1): S37 abstr. P210, No. 2, Jun 2018. Available from: URL: http://​journals.​sagepub.​com/​doi/​full/​10.​1177/​2047487318786175​ [abstract] - Germany
Metadaten
Titel
Alirocumab
Myalgia and severe depressive disorder: 2 case reports
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-49853-7

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Sibutramine

Case report

Paracetamol

Case report

Glucose

Case report

Tretinoin